Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fritsche

Showing results (91-100 of 214) with videos related to

Pageof 22
Sort By:
Diagnostic Microbiology and Infectious Disease|October 3, 2007
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC valuesRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|June 1, 2005
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogensJennifer M Streit, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 15, 2006
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)Kelley A Fedler, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2008
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureusThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infectionsThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
International Journal of Antimicrobial Agents|November 23, 2006
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Pageof 22

Showing results (91-100 of 214) with videos related to

Sort By:
Pageof 22
Diagnostic Microbiology and Infectious Disease|October 3, 2007
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC valuesRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|June 1, 2005
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogensJennifer M Streit, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 15, 2006
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)Kelley A Fedler, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2008
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureusThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross, Helio S Sader, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infectionsThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.
International Journal of Antimicrobial Agents|November 23, 2006
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
International Journal of Antimicrobial Agents|January 24, 2007
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross, Thomas R Fritsche, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocciRonald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Pageof 22